Literature DB >> 15824090

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.

Remedios Guna1, Carlos Muñoz, Victoria Domínguez, Angeles García-García, Jorge Gálvez, Jesús-Vicente de Julián-Ortiz, Rafael Borrás.   

Abstract

OBJECTIVES: To compare the activity of linezolid with a range of drugs used in the treatment of Mycobacterium kansasii infections.
RESULTS: The percentages of resistant isolates against isoniazid, rifampicin and ethambutol were 2.9%, 1.9% and 2.9%, respectively. All isolates were susceptible to clarithromycin and moxifloxacin both with MIC(90) values of 0.125 mg/L. Linezolid was active against all isolates with MIC(50) and MIC(90) values of 0.5 and 1 mg/L, respectively, both below the susceptibility breakpoint established for mycobacteria.
CONCLUSION: Linezolid, clarithromycin or moxifloxacin, could be used as alternative drugs for treatment of infections due to rifampicin-resistant isolates as well as short-course or intermittent therapy of M. kansasii lung disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824090     DOI: 10.1093/jac/dki111

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.

Authors:  Shashikant Srivastava; Jotam Pasipanodya; Carleton M Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Authors:  Zofia Bakuła; Magdalena Modrzejewska; Lian Pennings; Małgorzata Proboszcz; Aleksandra Safianowska; Jacek Bielecki; Jakko van Ingen; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  [Nontuberculous mycobacteria in sputum : Recommendations for diagnosis and treatment].

Authors:  J Rademacher
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

4.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

5.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  Mycobacterium kansasii Subtype I Is Associated With Clarithromycin Resistance in China.

Authors:  Yanming Li; Yu Pang; Xunliang Tong; Huiwen Zheng; Yanlin Zhao; Chen Wang
Journal:  Front Microbiol       Date:  2016-12-26       Impact factor: 5.640

Review 7.  Selection of appropriate analytical tools to determine the potency and bioactivity of antibiotics and antibiotic resistance.

Authors:  Nishant A Dafale; Uttam P Semwal; Rupak K Rajput; G N Singh
Journal:  J Pharm Anal       Date:  2016-05-24

8.  Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.

Authors:  Vitalii Litvinov; Marina Makarova; Ksenia Galkina; Elena Khachaturiants; Maria Krasnova; Lidia Guntupova; Svetlana Safonova
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

9.  Therapy for Mycobacterium kansasii Infection: Beyond 2018.

Authors:  Michelle S DeStefano; Carolyn M Shoen; Michael H Cynamon
Journal:  Front Microbiol       Date:  2018-09-24       Impact factor: 5.640

Review 10.  Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.

Authors:  Akosua Adom Agyeman; Richard Ofori-Asenso
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-06-22       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.